Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Joffe

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Chemistry & Biodiversity|May 30, 2009
Biological evaluation of ent-narciclasine, ent-lycoricidine, and certain enantiomerically-related congenersMaria Matveenko, Martin G Banwell, Max Joffe, et al.
Journal of Immunological Methods|May 18, 2010
A method for extracting tissue proteins for use in lymphocyte function assaysHayley C Moon, Max Joffe, Helen E Thomas, et al.
International Immunology|March 2, 2012
Residual methylprednisolone suppresses human T-cell responses to spleen, but not islet, extracts from deceased organ donorsMax Joffe, Andra S Necula, Rochna Chand, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2009
Discovery of CYT997: a structurally novel orally active microtubule targeting agentChristopher J Burns, Michael F Harte, Xianyong Bu, et al.
Bioorganic & Medicinal Chemistry Letters|January 9, 2009
Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMSChristopher J Burns, Michael F Harte, Xianyong Bu, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2011
The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivoChristopher J Burns, Emmanuelle Fantino, Andrew K Powell, et al.
Molecular Cancer Therapeutics|November 6, 2009
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivoChristopher J Burns, Emmanuelle Fantino, Ian D Phillips, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2009
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)Christopher J Burns, David G Bourke, Laura Andrau, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Chemistry & Biodiversity|May 30, 2009
Biological evaluation of ent-narciclasine, ent-lycoricidine, and certain enantiomerically-related congenersMaria Matveenko, Martin G Banwell, Max Joffe, et al.
Journal of Immunological Methods|May 18, 2010
A method for extracting tissue proteins for use in lymphocyte function assaysHayley C Moon, Max Joffe, Helen E Thomas, et al.
International Immunology|March 2, 2012
Residual methylprednisolone suppresses human T-cell responses to spleen, but not islet, extracts from deceased organ donorsMax Joffe, Andra S Necula, Rochna Chand, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2009
Discovery of CYT997: a structurally novel orally active microtubule targeting agentChristopher J Burns, Michael F Harte, Xianyong Bu, et al.
Bioorganic & Medicinal Chemistry Letters|January 9, 2009
Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMSChristopher J Burns, Michael F Harte, Xianyong Bu, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2011
The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivoChristopher J Burns, Emmanuelle Fantino, Andrew K Powell, et al.
Molecular Cancer Therapeutics|November 6, 2009
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivoChristopher J Burns, Emmanuelle Fantino, Ian D Phillips, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2009
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)Christopher J Burns, David G Bourke, Laura Andrau, et al.
Pageof 1